Targeting Biomarkers and the FDA’s Biomarker Qualification Framework

JAMA Psychiatry 2026

View at publisher
Authors: Hamed Ekhtiari, Arshiya Sangchooli, Alex Fornito, Michael D. Fox
DOI: 10.1001/jamapsychiatry.2026.0590
Cited by: 1
References: 6

Abstract

This Viewpoint argues for adding a new category, targeting biomarkers, to the US Food and Drug Administration’s biomarker qualification framework.

Fields of Study & Subjects

Statistical Methods in Clinical Trials GDF15 and Related Biomarkers TGF-β signaling in diseases

Publication details

Journal / source
JAMA Psychiatry
Publisher
American Medical Association (AMA)
Volume
83
Issue
6
Pages
555–555
Publication date
15 April 2026
Language
EN